Tag: aurobindo_pharma_limited
-
FTC Mandates Divestiture in Aurobindo-Lannett Merger to Curb Drug Costs
The Federal Trade Commission has ordered Aurobindo Pharma Limited to divest four generic drug products as part of its $250 million acquisition of Lannett Company Inc., aiming to prevent higher drug costs for American patients.
BusinessLaw EnforcementHealthEconomyLegalMedical Science Federal Trade CommissionFTCAurobindo Pharma LimitedLannett Company Inc.generic drugsdrug costsdivestiture